Summary
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
